Tevogen Bio Holdings Inc. Total Liabilities
Tevogen Bio Holdings Inc. total liabilities. Based on the latest financial reports, Tevogen Bio Holdings Inc. (TVGN) has total liabilities worth $13.62 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TVGN asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tevogen Bio Holdings Inc. (2022–2026)
Total liabilities of Tevogen Bio Holdings Inc. from 2022 to 2026. This chart illustrates how Tevogen Bio Holdings Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Tevogen Bio Holdings Inc. Competitors by Total Liabilities
The table below lists competitors of Tevogen Bio Holdings Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inhwa Precision Co. Ltd
KQ:101930
|
Korea | ₩131.24 Billion |
|
Ji-Haw Industrial Co Ltd
TW:3011
|
Taiwan | NT$1.25 Billion |
|
Augwind Energy Tech Storage Ltd
TA:AUGN
|
Israel | ILA12.86 Million |
|
Chian Hsing Forging Industrial Co Ltd
TWO:4528
|
Taiwan | NT$1.46 Billion |
|
Helbor Empreendimentos S.A
SA:HBOR3
|
Brazil | R$3.91 Billion |
|
3S KOREA Co. Ltd
KQ:060310
|
Korea | ₩14.25 Billion |
|
Softcat plc
LSE:SCT
|
UK | GBX919.96 Million |
Liability Composition Analysis (2022–2026)
This chart breaks down Tevogen Bio Holdings Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Tevogen Bio Holdings Inc. assets under control.
Liquidity & Leverage Metrics
Tevogen Bio Holdings Inc. Total Liabilities Ratios Explained
Tevogen Bio Holdings Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.88 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tevogen Bio Holdings Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tevogen Bio Holdings Inc. (2022–2026)
The table below shows the annual total liabilities of Tevogen Bio Holdings Inc. from 2022 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | $12.62 Million | +24.49% |
| 2025-06-30 | $10.14 Million | -89.86% |
| 2024-06-30 | $99.93 Million | +139.71% |
| 2023-06-30 | $41.69 Million | +72.65% |
| 2022-06-30 | $24.15 Million | -- |
About Tevogen Bio Holdings Inc.
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B… Read more